Precision Biosensor, Inc. (KOSDAQ:335810)

Market Cap	33.01B -5.3%
Revenue (ttm)	23.66B +22.2%
Net Income	-6.35B
EPS	-365.34
Shares Out	21.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,183
Open	1,490.00
Previous Close	1,488.00
Day's Range	1,473.00 - 1,505.00
52-Week Range	1,106.00 - 3,505.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Precision Biosensor

Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea.

• Industry: Measuring and Controlling Devices, not elsewhere classified
• Founded: 2009
• Employees: 98
• Stock Exchange: KOSDAQ
• Ticker Symbol: 335810

Financial Performance

In 2025, Precision Biosensor's revenue was 19.93 billion, an increase of 4.14% compared to the previous year's 19.13 billion. Losses were -10.02 billion, 37.2% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 12, 2026

Data Sources Report a data error